At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 277 enrolled
Drug / intervention
Apremilast +1 moredrug
Likely dose
Apremilast 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life
In Brief
A Phase 4 clinical trial evaluating Apremilast and Placebo for Psoriasis. Completed, enrolled 277 participants across 72 sites in 6 countries.
Detailed Summary
The primary objective of the study is to assess the impact of treatment with apremilast 30 mg twice daily for 16 weeks, compared to placebo, on health-related quality of life (QOL) in adults with manifestations of plaque psoriasis and impaired quality of life.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesFrance, Germany, Italy, Spain, Switzerland, United Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartMar 2019
Primary CompletionFeb 2021
Study CompletionNov 2021
TodayJul 2026
First PostedDec 13, 2018
Enrollment StartMar 28, 2019
Primary CompletionFeb 1, 2021
Study CompletionNov 3, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.6 years ago
Interventions
Apremilastdrug
Apremilast 30 mg tablets taken orally twice a day.
Placebodrug
Placebo tablets taken orally twice a day